ライフサイエンスコーパス: human papillomavirus

1 ng against human papillomavirus and low-risk human papillomavirus.

2 dy, we assessed the importance of the CTD of human papillomavirus 11 (HPV11) E1 in vivo, using a cell

3 Human papillomavirus 11 (HPV11) is an etiological agent

4 ed tetracycline-inducible vector system, and human papillomavirus 16 (HPV 16) E6 and E7 gene-immortal

5 Recent studies have reported evidence of human papillomavirus 16 (HPV-16) in a very high proporti

6 Both human papillomavirus 16 (HPV16) and bovine papillomaviru

7 In agreement with previous studies, we found human papillomavirus 16 (HPV16) and HPV18 in oropharynge

8 The structure of human papillomavirus 16 (HPV16) complexed with H16.U4 fr

9 To replicate the double-stranded human papillomavirus 16 (HPV16) DNA genome, viral protei

10 The association between oral human papillomavirus 16 (HPV16) DNA load and infection c

11 rect cleavage of capsid-associated L2 during human papillomavirus 16 (HPV16) infection remains poorly

12 Human papillomavirus 16 (HPV16) is causative in many hum

13 Human papillomavirus 16 (HPV16) is the most prevalent HR

14 Human papillomavirus 16 (HPV16) is the most prevalent on

15 eatment, dramatically decreased infection of human papillomavirus 16 (HPV16) pseudovirus (PsV).

16 ed a novel interaction between Rint1 and the human papillomavirus 16 (HPV16) transcription and replic

17 s, including bovine papillomavirus (BPV) and human papillomavirus 16 (HPV16), associate with the cell

18 A human papillomavirus 16 (HPV16)-targeted version of the

19 iority 1 month after the last dose of 2-dose human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/

20 Human papillomavirus 18 (HPV18) is an etiologic agent of

21 Human papillomavirus 18 (HPV18) is the second most commo

22 t of the notion that IFI16 can also restrict human papillomavirus 18 (HPV18) replication.

23 ecipitated with the BPV-1 E2 protein, as did human papillomavirus 31 (HPV-31) E2, which also colocali

24 The association between human papillomavirus 31 (HPV31) DNA loads and the risk o

25 n Australia, high uptake of the quadrivalent human papillomavirus (4vHPV) vaccine has led to reductio

26 Human papillomavirus 58 (HPV58) is found in 10 to 18% of

27 a phosphorylated peptide motif derived from human papillomavirus 8 (HPV-8), the E2 hinge region incl

28 -26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33,

29 cell carcinoma (SCC) is associated with both human papillomavirus and HIV infection.

30 und for male circumcision protecting against human papillomavirus and low-risk human papillomavirus.

31 ients in RTOG 0129 (2002 to 2005) with known human papillomavirus and smoking status.

32 The following search terms were used: "human papillomavirus" and "cutaneous squamous cell carci

33 CC with known p16 tumor status (surrogate of human papillomavirus) and cigarette smoking history (pac

34 Human papillomaviruses are the causative agents of cervi

35 lief with the recently described epidemic of human papillomavirus-associated head and neck squamous c

36 r T cell responses in complete regression of human papillomavirus-associated metastatic cervical canc

37 regarding the association between beta-genus human papillomavirus (beta-HPV) and cutaneous squamous c

38 evaluated the association between beta genus human papillomaviruses (betaPV) and keratinocyte carcino

39 Some viruses, like the human papillomaviruses, can cause cancer directly.

40 The virus coat (capsid) of the human papillomavirus contains major (L1) and minor (L2)

41 , Escherichia coli, influenza virus, cancer, human papillomavirus, dopamine, glutamic acid, IgG, IgE,

42 Human papillomaviruses enter host cells via a clathrin-i

43 ility of certain viruses (hepatitis B and C, human papillomavirus, etc) to cause cancer has been time

44 Oral human papillomavirus genotype 16 (HPV16) infection cause

45 major (L1) and minor (L2) capsid proteins of human papillomavirus genotype 45 (HPV45).

46 Human papillomavirus genotype-specific concordance is mo

47 itive for the p16 protein, an indicator that human papillomavirus had a role in the causation of the

48 Human papillomavirus has a prognostic role in R/M diseas

49 e.g., atherosclerosis, cancer), viral (e.g., human papillomavirus, herpes virus) and bacterial (e.g.,

50 ning of all HIV-infected women regardless of human papillomavirus history or sexual practices.

51 awareness of the tremendous global impact of human papillomavirus (HPV) -caused cancers, refocus the

52 compared regimens including 2 doses (2D) of human papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine

53 igated the natural history of high-risk anal human papillomavirus (HPV) among a multinational group o

54 transmitted diseases treatment guidelines on human papillomavirus (HPV) and anogenital warts (AGWs),

55 n antiretroviral therapy (ART) and high-risk human papillomavirus (HPV) and cervical lesions in women

56 of the DNA tumor viruses, including E7 from human papillomavirus (HPV) and E1A from adenovirus, as p

57 ave been mixed on whether naturally acquired human papillomavirus (HPV) antibodies may protect agains

58 Head and neck cancers positive for human papillomavirus (HPV) are exquisitely radiosensitiv

59 Vaccines against human papillomavirus (HPV) are recommended for routine u

60 Specific types of human papillomavirus (HPV) are strongly associated with

61 High-risk strains of human papillomavirus (HPV) are the causative agents of c

62 Laboratories now can choose from >100 human papillomavirus (HPV) assays for cervical screening

63 The human papillomavirus (HPV) capsid is composed of the maj

64 During the entry process, the human papillomavirus (HPV) capsid is trafficked to the t

65 The human papillomavirus (HPV) capsid protein L2 is essentia

66 ithin the endosome triggers uncoating of the human papillomavirus (HPV) capsid, whereupon host cyclop

67 Importance: Human papillomavirus (HPV) causes an increasing proporti

68 Human papillomavirus (HPV) causes an increasing proporti

69 Human papillomavirus (HPV) causes the majority of oropha

70 the prevalence and risk factors for genital human papillomavirus (HPV) detection among men who deny

71 norectal swabs for cytologic examination and human papillomavirus (HPV) detection and genotyping.

72 amine the temporal relationship between oral human papillomavirus (HPV) detection and risk of head an

73 -CoV), Mycobacterium tuberculosis (MTB), and human papillomavirus (HPV) DNA based on a colorimetric p

74 Methylation of the human papillomavirus (HPV) DNA has been proposed as a no

75 Detection of human papillomavirus (HPV) DNA in genital samples may no

76 Detection of human papillomavirus (HPV) DNA in oral rinses is associa

77 iltrating T cells selected when possible for human papillomavirus (HPV) E6 and E7 reactivity (HPV-TIL

78 eins are amongst the least understood of the Human Papillomavirus (HPV) encoded gene products.

79 cell differentiation-dependent regulation of human papillomavirus (HPV) gene expression is required f

80 Here we describe human papillomavirus (HPV) genomes that express marker p

81 and minor (L2) capsid proteins of oncogenic human papillomavirus (HPV) genotype 31 (HPV31) to determ

82 e has led to reductions in the prevalence of human papillomavirus (HPV) genotypes 6, 11, 16, and 18 i

83 The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT) st

84 Human papillomavirus (HPV) high-risk genotypes such as H

85 Australia instituted funded female human papillomavirus (HPV) immunization in 2007, followe

86 ly representative prevalence data on genital human papillomavirus (HPV) in males in the United States

87 9-valent viruslike particle vaccine against human papillomavirus (HPV) includes the HPV types in the

88 Cutaneous beta human papillomavirus (HPV) infection across cutaneous an

89 Limited data are available on human papillomavirus (HPV) infection among human immunod

90 obiota (VM) may influence risk of persistent Human Papillomavirus (HPV) infection and cervical carcin

91 to analyze the associations between cervical human papillomavirus (HPV) infection and human immunodef

92 luated the risk factors associated with oral human papillomavirus (HPV) infection and oral lesions in

93 n about the type-specific prevalence of anal human papillomavirus (HPV) infection and risk factors fo

94 Human papillomavirus (HPV) infection distinctly alters m

95 s the risk of sequential acquisition of anal human papillomavirus (HPV) infection following a type-sp

96 Lesbians and bisexual women are at risk for human papillomavirus (HPV) infection from female and mal

97 Human Papillomavirus (HPV) infection has been recognized

98 however, its association with cervicovaginal human papillomavirus (HPV) infection has not been studie

99 ciation between vaginal douching and genital human papillomavirus (HPV) infection have found contrary

100 thesized to explain the excess in detectable human papillomavirus (HPV) infection in Latin America, v

101 Human Papillomavirus (HPV) infection involves multiple s

102 Although the risk of human papillomavirus (HPV) infection is greatest in youn

103 The epidemiology of penile human papillomavirus (HPV) infection is not well underst

104 Oncogenic human papillomavirus (HPV) infection is the cause of nea

105 Studies of the natural history of human papillomavirus (HPV) infection require reproducibl

106 Human papillomavirus (HPV) infection, a primary cause of

107 investigated bereavement in association with human papillomavirus (HPV) infection, both HPV16 and oth

108 cell carcinomas (OPSCCs) is attributable to human papillomavirus (HPV) infection.

109 as been associated with an increased risk of human papillomavirus (HPV) infection.

110 ssociated with tobacco or alcohol use and/or human papillomavirus (HPV) infection.

111 have sex with men (MSM) are at high risk for human papillomavirus (HPV) infection; vaccination is rec

112 Although new human papillomavirus (HPV) infections can occur at all a

113 The clustering of human papillomavirus (HPV) infections in some individual

114 examined the concordance of penile and oral human papillomavirus (HPV) infections in the United Stat

115 Prevalence of human papillomavirus (HPV) infections was assessed among

116 We conducted a critical review of human papillomavirus (HPV) integration into the host gen

117 High-risk human papillomavirus (HPV) is a causative agent for an i

118 Human papillomavirus (HPV) is a common sexually transmit

119 Human papillomavirus (HPV) is a recently identified caus

120 Human papillomavirus (HPV) is a significant oncogenic vi

121 The human papillomavirus (HPV) is an etiologic agent associa

122 Human papillomavirus (HPV) is causally associated with a

123 Persistent infection with oncogenic Human Papillomavirus (HPV) is necessary for cervical car

124 d immunity in preventing newly acquired oral human papillomavirus (HPV) is not well understood.

125 Human papillomavirus (HPV) is now established as the pri

126 The two licensed bivalent and quadrivalent human papillomavirus (HPV) L1 (the major papillomavirus

127 The presence of neutralizing epitopes in human papillomavirus (HPV) L1 virus-like particles (VLPs

128 The human papillomavirus (HPV) life cycle is tightly linked

129 The human papillomavirus (HPV) life cycle is tightly linked

130 Population- wide vaccination against human papillomavirus (HPV) linked to cervical screening,

131 The human papillomavirus (HPV) major structural protein L1 c

132 Naturally induced serum antibodies against human papillomavirus (HPV) may affect risks of subsequen

133 cularly those in immunocompromised patients, human papillomavirus (HPV) may be an important factor.

134 Recent birth cohorts vaccinated against human papillomavirus (HPV) may be protected against up t

135 s been attributed to an increasing impact of human papillomavirus (HPV) on disease etiology.

136 Recently, the human papillomavirus (HPV) oncoprotein E6 has been ident

137 The human papillomavirus (HPV) plays a central role in cervi

138 The E7 oncoprotein of the high-risk human papillomavirus (HPV) plays a major role in HPV-ind

139 We assessed human papillomavirus (HPV) prevalence among HPV-16/18-va

140 From evaluations in human papillomavirus (HPV) protection models in rabbits

141 The human papillomavirus (HPV) replication cycle is tightly

142 cervical cancer in England, UK, will change: human papillomavirus (HPV) screening will be the primary

143 Importance: Pathology-based measures of human papillomavirus (HPV) status are routinely obtained

144 Pathology-based measures of human papillomavirus (HPV) status are routinely obtained

145 aryngeal cases with information available on human papillomavirus (HPV) status indicated that this as

146 rammed death ligand 1 (PD-L1) expression and human papillomavirus (HPV) status.

147 In 2000, the Hybrid Capture 2 human papillomavirus (HPV) test was approved by the U.S.

148 Using primary human papillomavirus (HPV) testing for cervical screenin

149 Human papillomavirus (HPV) testing is used in primary ce

150 nd compared it with post-treatment high-risk human papillomavirus (HPV) testing.

151 ab specimens were collected for cytology and human papillomavirus (HPV) testing.

152 Inexpensive and easy-to-perform human papillomavirus (HPV) tests are needed for primary

153 We used a transmission dynamic model of human papillomavirus (HPV) to investigate the effect of

154 e influence on biopsy and treatment rates of human papillomavirus (HPV) triage of cytology showing at

155 e colposcopic impression, HSIL cytology, and human papillomavirus (HPV) type 16 positivity.

156 8, Scotland launched routine vaccination for human papillomavirus (HPV) types 16 and 18, targeted at

157 ta on the relative carcinogenic potential of human papillomavirus (HPV) types among women infected wi

158 We designed a universal human papillomavirus (HPV) typing assay based on target

159 Incoming human papillomavirus (HPV) utilize vesicular transport t

160 Case reports have suggested a link between human papillomavirus (HPV) vaccination and development o

161 Human papillomavirus (HPV) vaccination is still not reac

162 ling studies have been widely used to inform human papillomavirus (HPV) vaccination policy decisions;

163 Human papillomavirus (HPV) vaccination programmes were f

164 Prophylactic human papillomavirus (HPV) vaccination programs constitu

165 Reducing the number of doses in the human papillomavirus (HPV) vaccination regimen from 3 to

166 Human papillomavirus (HPV) vaccination targeting females

167 Expanding routine human papillomavirus (HPV) vaccination to adults could b

168 ctiveness of providing 3-doses of nonavalent human papillomavirus (HPV) vaccine (9vHPV) to females ag

169 Uptake of human papillomavirus (HPV) vaccine among girls in the Du

170 ation of antibody response following reduced human papillomavirus (HPV) vaccine doses has not been de

171 ng women in the United States completing the human papillomavirus (HPV) vaccine doubled.

172 Human papillomavirus (HPV) vaccine effectiveness and her

173 mer), which targets a vaccine antigen in the human papillomavirus (HPV) vaccine Gardasil.

174 Uptake of human papillomavirus (HPV) vaccine in the United States

175 In the United States, human papillomavirus (HPV) vaccine is recommended for 11

176 The quadrivalent human papillomavirus (HPV) vaccine is recommended for al

177 Decreasing human papillomavirus (HPV) vaccine prices makes scaling

178 The quadrivalent human papillomavirus (HPV) vaccine was licensed for use

179 Human papillomavirus (HPV) vaccine was recommended in 20

180 A 9-valent human papillomavirus (HPV) vaccine, licensed in 2014, pr

181 ted partial cross-protection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16

182 e vaccination with the prophylactic bivalent human papillomavirus (HPV) vaccine.

183 Human papillomavirus (HPV) vaccines are ideally administ

184 The human papillomavirus (HPV) vaccines consist of major cap

185 First generation bivalent and quadrivalent human papillomavirus (HPV) vaccines have been introduced

186 Although available human papillomavirus (HPV) vaccines have high efficacy a

187 Effectiveness of human papillomavirus (HPV) vaccines in the context of bo

188 A substantial effect of human papillomavirus (HPV) vaccines on reducing HPV-rela

189 The association between partner human papillomavirus (HPV) viral load and incident HPV d

190 Circumcision and lower human papillomavirus (HPV) viral loads in men are possib

191 The high prevalence of human papillomavirus (HPV), the most common sexually tra

192 control group, GUWE treated DCs pulsed with human papillomavirus (HPV)-16 E6/E7 peptides significant

193 neoplastic transformation of human cells, so human papillomavirus (HPV)-associated cancers will also

194 ole in the proteasomal degradation of p53 in human papillomavirus (HPV)-associated cancers.

195 Trends in human papillomavirus (HPV)-associated cervical lesions c

196 with men (MSM) bear a substantial burden of human papillomavirus (HPV)-associated disease, prospecti

197 Purpose Human papillomavirus (HPV)-associated oropharyngeal squa

198 However, the role of gammadelta T cells in human papillomavirus (HPV)-associated uterine cervical S

199 ndrome and in a variety of cancers including human papillomavirus (HPV)-caused cervical cancer.

200 Importance: Human papillomavirus (HPV)-induced anogenital lesions ar

201 sustained in CIN3, consistent with high-risk human papillomavirus (HPV)-induced tumor suppressor inac

202 ion levels were significantly upregulated in human papillomavirus (HPV)-infected cell lines and tissu

203 Human papillomavirus (HPV)-negative head and neck squamo

204 Human papillomavirus (HPV)-negative oropharyngeal squamo

205 Human papillomavirus (HPV)-positive (HPV(+)) and HPV-neg

206 Patients with human papillomavirus (HPV)-positive head and neck squamo

207 The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer

208 The burden of human papillomavirus (HPV)-positive oropharyngeal squamo

209 ancerization of the skin from which multiple human papillomavirus (HPV)-positive squamous cell carcin

210 Compared to primary human papillomavirus (HPV)-positive tumors, many recurre

211 The effective management of women with human papillomavirus (HPV)-positive, cytology-negative r

212 Peptide-based therapeutic vaccines against human papillomavirus (HPV)-related cancers are usually d

213 experienced an increase in the incidence of human papillomavirus (HPV)-related cancers that are not

214 m of this study was to determine the risk of human papillomavirus (HPV)-related carcinomas and premal

215 As the demand for human papillomavirus (HPV)-related cervical screening in

216 ed patients develop persistent, stigmatizing human papillomavirus (HPV)-related cutaneous and genital

217 The incidence of human papillomavirus (HPV)-related head and neck squamou

218 urpose Cancer survivors are at high risk for human papillomavirus (HPV)-related morbidities; we estim

219 Patients with human papillomavirus (HPV)-related oropharyngeal cancer

220 Importance: An escalating incidence of human papillomavirus (HPV)-related oropharyngeal squamou

221 ol (AJCC/UICC) staging system, developed for human papillomavirus (HPV)-unrelated disease, discrimina

222 from a persistent infection with a high-risk human papillomavirus (HPV).

223 ical cancer, a disease principally caused by human papillomavirus (HPV).

224 cell papillomas are common lesions caused by human papillomavirus (HPV).

225 rare malignancy associated with infection by human papillomavirus (HPV).

226 warts and cancers related to infection with human papillomavirus (HPV).

227 ng of E6AP by the E6 oncoprotein of distinct human papillomaviruses (HPV) contributes to the developm

228 Amplification of human papillomaviruses (HPV) is dependent on the ATM DNA

229 Human papillomaviruses (HPV) replicate their genomes in

230 s a consequence of persistent infection with human papillomaviruses (HPV).

231 increased expression of the major high-risk human-papillomavirus (HPV) oncogenes E6 and E7 in basal

232 years with cytology (cytologic tests without human papillomavirus [HPV] tests).

233 eplication (human cytomegalovirus [HCMV] and human papillomavirus [HPV]) and transcription (HSV-1, HC

234 le differences in infection-related (HIV and human papillomavirus [HPV]) cancers.

235 sitivity and limit of detection of high-risk human papillomavirus (HPV16), compared to the standard s

236 Infections with high-risk human papillomaviruses (HPVs) are a major cause of anoge

237 Oncogenic human papillomaviruses (HPVs) are closely linked to majo

238 Human papillomaviruses (HPVs) are highly prevalent and p

239 At least 15 high-risk human papillomaviruses (HPVs) are linked to anogenital p

240 Human papillomaviruses (HPVs) are the etiological agents

241 beta-Human papillomaviruses (HPVs) cause near ubiquitous late

242 Infection by human papillomaviruses (HPVs) has been implicated in the

243 The infectious process of human papillomaviruses (HPVs) has been studied considera

244 High-risk human papillomaviruses (HPVs) infect epithelial cells an

245 Human papillomaviruses (HPVs) infect the epidermis as we

246 The life cycle of human papillomaviruses (HPVs) is dependent upon differen

247 High-risk human papillomaviruses (HPVs) link their life cycle to e

248 Despite preventive vaccines for oncogenic human papillomaviruses (HPVs), cervical intraepithelial

249 Oncoviruses, including human papillomaviruses (HPVs), Epstein-Barr virus (EBV),

250 Persistent infection by specific oncogenic human papillomaviruses (HPVs), including HPV58, has been

251 k of many cancers, including those caused by human papillomaviruses (HPVs).

252 High-risk human papillomavirus (HR-HPV) causes nearly 100% of cerv

253 The risk of incident high-risk human papillomavirus (HR-HPV) infection associated with

254 Carolina, to compare clearance of high-risk human papillomavirus (HR-HPV) infection between ethnicit

255 The risk of anal cancer due to high-risk human papillomavirus (HR-HPV) is higher in women living

256 18/45 genotype assay (AHPV GT) for high-risk human papillomavirus (hrHPV) detection, clinical perform

257 cervical squamous cell carcinomas, high-risk human papillomavirus (HRHPV) DNA is usually integrated i

258 High-risk human papillomavirus (hrHPV) testing to triage women wit

259 Background: High-risk human papillomavirus (hrHPV) testing to triage women wit

260 PV-related disease.IMPORTANCE High-risk-type human papillomaviruses (hrHPVs) cause 5% of all cancer c

261 Universal vaccination against the human papillomavirus, ideally with the nine-valent vacci

262 Human papillomaviruses infect mucosal and cutaneous epit

263 Human papillomavirus infection accounts for APOBEC3B upr

264 on; 33.9% (95% CI: 24.3-43.5%) for high-risk human papillomavirus infection from cervical samples and

265 counseled to recognize the signs of genital human papillomavirus infection.

266 aced on the discoveries made in the study of human papillomaviruses, Merkel cell carcinoma-associated

267 Human papillomavirus-negative head and neck squamous cel

268 a normal Pap test are positive for oncogenic human papillomavirus (oncHPV) types is important for set

269 Analysis of MATH and outcome in human-papillomavirus-positive oropharyngeal squamous cel

270 Human papillomavirus prevalence and determinants of geno

271 of C57BL/6 mice with a replication-defective human papillomavirus pseudovirus (HPV PsV) expressing HS

272 Recent evidence shows that quadrivalent human papillomavirus (qHPV) vaccination in men who have

273 protocols on patient-derived xenografts from human papillomavirus-related (HPV(+)) head and neck squa

274 Human papillomavirus-related (HPV+) oropharyngeal cancer

275 C was also associated with increased risk of human papillomavirus-related cancers, including anal can

276 Human papillomavirus-related oropharyngeal carcinoma (HP

277 Human papillomavirus replication is accomplished in conc

278 The beta genus of human papillomaviruses (ss-HPV) includes approximately 5

279 se; therefore, stratification of patients by human papillomavirus status in clinical trials is indica

280 or molecular characteristics, including age, human papillomavirus status, tumor grade and TP53 mutati

281 Established models have suggested that human papillomaviruses target the retinoblastoma (RB1) a

282 Human papillomavirus testing led to faster and more comp

283 anal cancers are attributable to persistent human papillomavirus type 16 (HPV-16) infection.

284 blished a cell-free in vitro system to study human papillomavirus type 16 (HPV16) assembly, a poorly

285 r to identify cellular factors that regulate human papillomavirus type 16 (HPV16) gene expression, ce

286 Although most cervical human papillomavirus type 16 (HPV16) infections become u

287 Several human papillomavirus type 16 (HPV16) oncoproteins contri

288 Oncogenic human papillomavirus type 16 (HPV16) or type 18 (HPV18)

289 Human papillomavirus type 16 DNA in oral rinses is commo

290 polycomb-mediated epigenetic methylations in human papillomavirus type 16 E7 expressing cells, and in

291 hree proteins from high-risk (HR-) oncogenic human papillomavirus type 58 (HPV58).

292 Human papillomavirus type 6 (HPV-6) and HPV-11 are the e

293 red for gene transduction by three oncogenic human papillomavirus types, HPV16, HPV18, and HPV31.

294 Human papillomavirus vaccination may represent an effica

295 Human papillomavirus vaccination, stratified by the numb

296 ne adjuvanted with aluminum hydroxide, and a human papillomavirus vaccine adjuvanted with aluminum hy

297 toxoid, and reduced acellular pertussis; and human papillomavirus vaccines) in addition to time postt

298 ANCE After internalization, the nonenveloped human papillomavirus virion uncoats in the endosome, whe

299 A recent clinical trial using the 9-valent human papillomavirus virus (HPV) vaccine has shown that

300 Human papillomavirus virus type 16 (HPV-16) and HPV-18 c